PAVmed Inc.

Analysts covering PAVmed have set an average twelve-month price target of $56.00, implying an extraordinary upside of over 840% from current levels. This consensus, despite mixed ratings, suggests that at least some analysts see significant undervaluation in PAVmed's current stock price relative to its long-term potential.

PAVmed's Q1 2024 actual EPS of -$78.60 dramatically missed the consensus estimate of -$50.20, signaling persistent and deeper-than-expected losses. This level of earnings underperformance raises serious questions about whether the lofty analyst price targets are grounded in realistic financial projections.

A buy signal was issued from a pivot bottom on July 8, 2025, with the stock gaining nearly 9% since. The short-term Moving Average and MACD also show buy signals, suggesting the stock may be building a base and could see near-term upward momentum if it breaks through key resistance levels.

Despite short-term buy signals, the stock remains within a wide and falling long-term trend. Technical models forecast a further decline of approximately 20.58% over the next three months, with the long-term Moving Average sitting above the short-term average — a classic configuration indicating continued downward pressure.

PAVmed's addition to the Russell 3000E Value Benchmark is a meaningful milestone, as index inclusion typically attracts passive institutional investment flows. With a mean analyst consensus of 'Buy' and an average target price of $36.00 — representing over 500% upside from its last close — some analysts view the stock as deeply undervalued.

Despite index inclusion and optimistic price targets, PAVmed's stock remains at penny-stock levels, with a consensus rating of only 'Hold' from a broader set of analysts. Only one out of three analysts rates it a buy, while one assigns a sell rating, reflecting deep uncertainty about whether the company can execute on its business model to justify any substantial rerating.